FINANCIAL EXPRESS

NOTICE I Resham Devi Surana, holding 3800 shares of Reliance Industries Limited, Registered office:3rd Floor, Maker Chambers IV,222 Nariman point, Mumbai - 400021, Folio No.075515197 bearing Share Certificate No.16820598, 16820599, 16820600, 16820601, 16820602 and 16820603 with distinctive nos. from 470218555 to 470218579, 470218580 to 470218604 470218605 to 470218629, 470218630 to 470218654, 470218655 to 470218679 and 470218680 to 470218704, consisting 25 shares each respectively, total 125 shares are lost and I have applied to the company for issue of duplicate share certificates. The public is hereby warned against purchasing or dealing in anyway with the share certificates. The company may issue duplicate share certificates if no objection is received within 15 days of the publication of the advertisement, after which no claim shall be entertained by

the company in that behalf. Resham Devi Surana Place: Mumbai Date:15th Aug,2020 Folio: 075515197

Life Insurance Aditya Birla Sun Life Insurance Company Ltd.

Regn. No.: 109. Regd Office: One Indiabulis Centre, Tower 1, 16th Floor, Jupiter Mill Compound, 841, Senapati Bapat Marx. Elphinstone Road, Mumbai - 400013 +91 22 4356 7000 | CIN: 99999MH2000PLC128110

NOTICE

Notice is hereby given that, w.e.f. 30/09/2020, Aditya Birla Sun Life Insurance Company Ltd. Pandharpur office shall be closed.

Aditya Birla Sun Life Insurance Company Ltd. Ambikar Arcade, 4075/4A Station Road, Pandharpur - 413304

Closing Premise:

Alternative Servicing Branch Aditya Birla Sun Life Insurance Company Ltd. Unit No. 3, Second Floor, "Guru Sharan Sankul" Muncipal House No. 165, Besides Chitle Clinic, Saat Rasta Solapur - 413001

2nd Floor, Millennium Tower, Bhandarkar Road, Deccan Gymkhana, Pune, Maharashtra - 411004 Place: Maharashtra Date: 15/08/2020 Authorised Signatory For Further details please contact

Aditya Birla Sun Life Insurance Company Limited Formerly Birla Sun Life Insurance Company Limited) Registered Office: One Indiabulis Centre, Tower 1, 16th Floor, Jupiter Mill Compound. 841, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400 013.

Call Toll Free: 1-800-270-7000 Website: www.adityabirlasunlifeinsurance.com "The Trade Logo, "Astryo Birlo Contof" Displayed Above to Owned By ADITYA BRILA MANAGEMENT CORPORATION PRIVATE LIMITED (Trademark Owner) And Used By ADITYA BRILA SUN LIFE INSURANCE COMPRNY LIMITED (ABSLE) under the License."

ADV-B/7/20-21/665

AKSH OPTIFIBRE LIMITED

Registered Office: F-1080, RIICO Industrial Area, Phase-III, Bhiwadi-301019 (Rajasthan) Corporate Office: A 32, 2nd Floor, Mohan Co-operative Indl. Estate, Mathura Road, New Delhi-110044 Live Smart Corporate Identification No. (CIN): L24305RJ1986PLC016132

EXTRACT OF STANDLOANE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2020 Rs. in lakhs except per share data Quarter Ended Year Ended Particulars Mar/20 Jun/19 Mar/20 Jun/20 (Unaudited) (Unaudited) Unaudited) (Audited) 4.173.34 5,760.82 7,849.31 25,514.44 Total income from operations (1.661.49) Net Profit for the period (before tax and exceptional items) (511.28) (151.98)(127.75)(511.88)(23,773,75)(119.06)(25.256.65)Net Profit for the period before tax (after exceptional items) Net Profit for the period after tax (after exceptional items) (343.05)(23,781.90)(86.34) (24,773.32) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive (23,939.19) (86.80) (24,933.96) Income (after tax)] (343.05)

			Rs. in	lakhs except	per share data
EX	TRACT OF CONSOLIDATED FINANCIAL RESU	JLTS FOR THE	QUARTER E	NDED JUN	IE 30, 2020
8.	Earnings Per Share (of Rs. 5/- each) Basic : Diluted:	(0.21) (0.21)	(0.21) (0.21)	(0.21) (0.21)	(0.21) (0.21)
7.	Other equity		100	23	18,320.95
6.	Paid-up Equity Capital (Face Value Rs.5 each)	8,134.90	8,134.90	8,134.90	8,134.90
					T. L. Martin Co., Co. Co., Co., Co., Co., Co., Co.,

S.			Year Ended		
No.	Particulars	Jun/20 (Unaudited)	Mar/20 (Unaudited)	Jun/19 (Unaudited)	Mar/20 (Audited)
1.	Total income from operations	4,934.08	6,778.39	10,239.78	30,272.68
2.	Net Profit for the period (before tax and exceptional items)	(1,272.83)	(1,277.73)	(532.87)	(4,729.37)
3,	Net Profit for the period before tax (after exceptional items)	(1,273.43)	(33,208.06)	(520.04)	(36,644.52)
4.	Net Profit for the period after tax (after exceptional items)	(1,107.44)	(33,118.73)	(501.19)	(35,930.50)
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	(1,157.59)	(33,879.43)	(565.72)	(36,321.91)
6.	Paid-up Equity Capital (Face Value Rs.5 each)	8,134.90	8,134.90	8,134.90	8,134.90
7.	Other equity				4,610.20
8.	Earnings Per Share (of Rs. 5/- each) Basic : Diluted:	(0.68) (0.68)	(20.36) (20.36)	(0.31) (0.31)	(22.08) (22.08)

under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015. The full format of the Quarterly results are available on the Company's website i.e. www.akshoptifibre.com and on the stock exchange websites i.e. www.bseindia.com & www.nseindia.com.

> For and on behalf of the Board of Directors of Aksh Optifibre Limited Dr. Kailash S Choudhari Chairman

> > DIN-00023824

Date: 14.08.2020

Place: United Kingdom

AJANTA SOYA LIMITED CIN L15494RJ1992PLC016617

Regd. Office & Works: SP-916, Phase - III, Industrial Area, Bhiwadi - 301019, Rajasthan, India Tel.: 911-6176727, 911-6128880

Corp. Office: 12th Floor, Bigjo's Tower, A-8, Netaji Subhash Place, Wazirpur District Centre, Delhi-110034 WEBSITE- www.ajantasoya.com, Email - cs@ajantasoya.com, Phone : 011-42515151; Fax : 011-42515100

	Extract of Standalone Un-audited Financial Re	esults for the quarter	ended 30" June, 202	0				
			(Rs.	in Lakhs except EPS				
1.		Standalone						
SI No.	Particulars	Quarter ended 30.06.2020	Quarter ended 30.06.2019	Year ended 31.03.2020				
1382.19		Un-Audited	Un-Audited	Audited				
1.	Total Income from operations*	19153.17	18912.68	76168.64				
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra Ordinary items)	147.25	189.81	1285.13				
3.	Net Profit/(Loss) for the period before tax (after Exceptional and /or Extraordinary items)	147.25	189.81	1285.13				
4.	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	68.43	134.08	979.84				
5.	Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after Tax)]	68.43	134.08	973.59				
6.	Equity Share Capital	1609.66	1609.66	1609.66				
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	3799.85 (as on 31.03.2020)	2826.26 (as on 31.03.2019)	3799.85 (as on 31.03.2020)				
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -							

Basic:

Diluted: "Total Income from operations consists of "Revenue from Operations and Other Income".

This Financial Results of the Company have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies to the extent applicable. The above is an extract of the detailed format of Un-audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI

Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the guarter ended 30° June, 2020 Un-audited financial Results are available on the Stock Exchange websites: www.bseindia.com and on Company's website www.ajantasoya.com. The above results were reviewed by the Audit committee, and thereafter approved by the Board of Directors in their meetings held on 14°

Previous year periods figures have been regrouped/reclassified/recasted, wherever necessary.

On behalf of the Board For Ajanta Soya Limited

0.83

Place: New Delhi Date: 14" August, 2020

Note:

Place: New Delhi

Date : 13" August 2020

Sushil Goyal Managing Director (DIN: 00125275)

6.09

ORIENT BELL LIMITED CIN: L14101UP1977PLC021546

Regd. Off.:- 8, Industrial Area, Sikandrabad - 203205, Dist. Bulandshahr, U. P. Corp. Off : Iris House, 16 Business Center, Nangal Raya, New Delhi-110 046 Tel.: +91-11-47119100, Email: investor@orientbell.com, Website: www.orientbell.com Statement of (Standalone & Consolidated) Unaudited Financial Results for the Quarter and Three Months Ended June 30, 2020

		Stane	lalone	(In ₹ Lakhs Consolidated		
SI. No.	Particulars		For the Quarter Ended on 30-06-2019			
1	Total income from Operations	4,273	12,068	4,273	12,068	
2	Net Profit for the period (before Tax and Exceptional items)	(1,827)	50	(1,865)	66	
3	Net Profit for the period (before Tax after Exceptional items)	(1,556)	50	(1,594)	66	
4	Net Profit for the period (after Tax after Exceptional items)	(1,104)	34	(1,142)	50	
5	Total Comprehensive Income for the period (Comprising Profit for the Period after Tax and Other Comprehensive Income after Tax)	17	17	17	17	
6	Paid up Equity Share Capital (Face value of Rs.10/- each)	1,430	1,426	1,430	1,426	
7	Earnings Per Share (of ₹ 10/- each)(For continuing and discontinued operations) (Not Annualised) 1. Basic 2. Diluted	(7.73) (7.73)	0.24 0.24	(7.99) (7.99)	0.35 0.35	

- 1. The above results were reviewed and recommended by the Audit Committee and then approved by the Board of Directors at their meeting held on 13th August, 2020. The financial results for the guarter and Three Months ended June 30, 2020 have been limited reviewed by the Statutory Auditors of the Company.
- 2. The above is an extract of the detailed format of quaterly/ annual financial results filed with the stock exchanges under regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The full format of the guarterly financial results is available on the stock exchange websites. (URL-www.nseindia.com and www.bseindia.com) and also on above mentioned Company's website at

orientbel

There is no change(s) in accounting policies which impact on net profit / loss, total comprehensive income or any other relevant financial item(s). Exceptional items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules

for and on behalf of the Board of Directors of Orient Bell Limited Madhur Daga

Managing Director

glenmark PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026. Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Statement of Unaudited Financial Results for the quarter ended 30th June, 2020

Standalone

(Rs. in Millions)

Consolidated

		Standalone				Consolidated			
Sr. No.	(Refer notes below)	Quarter ended 30-06-2020 (Unaudited)	Quarter ended 31-03-2020 (Audited)	Quarter ended 30-06-2019 (Unaudited)	Year ended 31-03-2020 (Audited)	Quarter ended 30-06-2020 (Unaudited)	Quarter ended 31-03-2020 (Audited)	Quarter ended 30-06-2019 (Unaudited)	Year ended 31-03-2020 (Audited)
1	Revenue from operations					3			
	(a) Net sales	16,524.45	15,616.96	14,552.33	64,912.00	23,092.83	27,112.73	22,836.04	103,972.2
	(b) Other operating income	304.77	460.38	435.60	2,214.31	355.04	562.16	392.75	2,437.4
	Total Revenue from operations	16,829.22	16,077.34	14,987.93	67,126.31	23,447.87	27,674.89	23,228.79	106,409.6
11	Other income	1,348.49	2,512.88	685.41	6,067.88		441.45	16.69	1,596.0
	The Charles of the Ch			100 march 100 miles 100 100 100 100 100 100 100 100 100 10	2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		2020 PM C C C C C C C C C C C C C C C C C C		
III	Total income (I + II)	18,177.71	18,590.22	15,673.34	73,194.19	24,033.01	28,116.34	23,245.48	108,005.7
IV	Expenses	100000000000000000000000000000000000000	100000000000000000000000000000000000000		10-01-10-17-27-01-17	2286/1072/1072/10	1000000000	75279751951951951	
	(a) Cost of materials consumed	5,917.41	5,496.43	5,193.73	22,519.81	7,041.92	5,940.01	6,086.05	25,414.7
	(b) Purchase of stock-in-trade	762.73	836.13	966.13	3,652.41	217.83	1,804.32	2,587.00	10,290.8
	(c) Changes in inventories of finished goods,								
	work-in-progress and stock-in-trade	(157.24)	518.87	(92.84)	487.68	823.91	2,016.17	(572.03)	1,280.8
	(d) Employee benefits expense	2,372.36	2,423.94	2,200.16	10,723.27	5,096.06	5,242.40	4,866.90	22,547.7
	(e) Finance costs	599.38	635.73	680.76	2,563.90	937.40	984.74	930.15	3,773.1
	(f) Depreciation and Amortisation expense	358.09	352.27	321.65	1,385.38	1,132.22	1,262.75	907.31	4,171.6
	(g) Other expenses	2,846.52	4,786.86	3,634.31	16,700.84	5,487.47	8,015.12	6,841.75	29,894.7
	Total expenses (IV)	260/01/10/20/2020	15,050.23				25,265.51	1000 A 0 100 A 0 100 PM C	
8	THE CHARLEST TO BE SEEN THE SEE THE SEE THE SEE THE SEE THE SEEN THE SEED OF T	12,699.25		12,903.90	58,033.29	20,736.81		21,647.13	97,373.7
. V	Profit/(loss) before exceptional items and tax (III-IV)	5,478.46	3,539.99	2,769.44	15,160.90		2,850.83	1,598.35	10,632.0
VI	Exceptional items (Refer note 6)	(279.90)	(185.54)		(185.54)	(279.90)	(328.76)	0.000	(328.70
VII	Profit/(loss) before tax (V-VI)	5,758.36	3,725.53	2,769.44	15,346.44	3,576.10	3,179.59	1,598.35	10,960.7
VIII	Tax expense :	700		200	255	53750	50	(9)	705
	Current tax	1,012.33	657.00	604.77	2,692.37	1,322.78	854.05	959.62	3,961.2
	Deferred tax	121.28	(423.34)	(113.76)	(891.41)	(287.10)	122.46	(454.08)	(760.2
IX	Profit/(loss) for the period from	Checkshellered	**************************************	83K 953500 - 5-061	400000000000000000000000000000000000000	W-seek services	CANADA-INDIA	11. November 2001	10.90527.5042304
1,500	continuing operations (VII - VIII)	4,624.75	3,491.88	2,278.43	13,545.48	2,540.42	2,203.08	1,092.81	7,759.7
v	Profit/(loss) for the period from	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0,101.00	2,2,0,,0	100000000	-10.101.1-	2,200.00	1,002.01	1,1,00
^	F (5) (1) (2) (2) (3) (3) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4		200				100	District	
VI	discontinuing operations (VII - VIII)		7.0						
XI	Tax expense of discontinuing operations :								
	Current tax		*0					1.0	
58000	Deferred tax	878	55	12		25	85	1071	
	Profit/(loss) for the period								
	from discontinuing operations (X - XI)	370	20	12		10.	(6	117.0	
XIII	Profit/(loss) for the period for continuing and								
	discontinuing operations (IX + XII)	4,624.75	3,491.88	2,278.43	13,545.48	2,540.42	2,203.08	1,092.81	7,759.7
XIV	Other comprehensive income	20022402300	An-Accommodate Alego	20-100-100-100-1	100-000 000-000 000	0.056703-050000	NG2W Security	ALC COMPANIANCE IN	A SSC NOVEMBER
(800)	A (i) Items that will not be reclassified to profit or loss	5.51	(46.08)	18.03	(88.83)	0.37	276.13	(38.25)	52.5
	(ii)Income tax relating to items that will not be	555.5	1,550	10.700000	(00.007)	51500	272222		8078387
	reclassified to profit or loss	(1.93)	16.42	(5.57)	34.61	(0.38)	(25.84)	1.22	15.0
	B (i) Items that will be reclassified to profit or loss	(1.55)	310.42	(0.07)	04,01	259.62	(2,066.47)	412.10	700000000 D 200000
		-	7.0			209.02	(2,066.47)	412.10	(2,248.3
	(ii)Income tax relating to items that will be	500	-			(40.00)	(400 E4)	04.00	(076.4)
	reclassified to profit or loss		0.400.00			(16.32)	(180.54)	24.99	(276.4
XV	Total comprehensive income	4,628.33	3,462.22	2,290.89	13,491.26	2,783.71	206.36	1,492.87	5,302.5
XVI	Total comprehensive income attributable to:								
	- Non-controlling interests	-	20		2	1.33	(1.67)	0.28	0.0
	- Owners of the Company	4,628.33	3,462.22	2,290.89	13,491.26	2,782.38	208.03	1,492.59	5,302.5
XVII	Other equity	1.0500000000	STORT DECEMBER 1	25.1370 25705200	131,980.47	introdusivegu	10 miles	A 100 CO	60,422.8
2007	Earning Per Share (EPS) (for continuing operations)								1856145549
^,,,,,	(of Re. 1/- each) (not annualised)*								
		16.39	12.38	8.07	48.00	9.00	7.81	3.87	27.5
	Basic EPS (in Rupees)		C-1113397035	000000000	2420677760000	100000000000000000000000000000000000000	735 557 555	200000000000000000000000000000000000000	500000000
VIV	Diluted EPS (in Rupees)	16.39	12.38	8.07	48.00	9.00	7.81	3.87	27.5
XIX	Earning Per Share (EPS) (for discontinuing operations)								
	(of Re. 1/- each) (not annualised)*								
	Basic EPS (in Rupees)	-	28	100	2	2	32		
25213	Diluted EPS (in Rupees)	8.43	42	34		2	592	1543	
XX	Earning Per Share (EPS) (for continuing and								
(All All	discontinuing operations)								
	400 NON 1 0 100 NON 1 1 TO THE SECOND SE	I							
	(of Re. 1/- each) (not annualised)*								
	(of Re. 1/- each) (not annualised)* Basic EPS (in Rupees)	16.39	12.38	8.07	48.00	9.00	7.81	3.87	27.5

* except for the year ended 31 March 2020

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results were reviewed by the Audit Committee at its meeting held on 13th August, 2020 and approved by the Board of Directors at their meetings held on
- The results for the quarter ended 30th June, 2020 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- Pursuant to the Taxation Law (Amendment) Ordinance 2019 ('Ordinance') Issued by Ministry of Law and Justice (Legislative Department) on 20th September 2019 which is effective 1st April 2019, domestic companies have the option to pay corporate Income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Company upon the amendment made an assessment of the Impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit and other exemptions. The Company has also re-measured its deferred tax liability following the clarification issued by Technical Implementation Group of Ind AS implementation Committee by applying the lower tax rate in measurement of deferred taxes only to extent that the deferred tax liabilities are expected to be reversed in the period during which it expects to be subject to lower tax rate.
- The Company completed its sale of intimate hygiene brand, VWash to Hindustan Unilever Limited during the quarter ended 30th June, 2020. 6 Exceptional item: Exceptional items in the standalone and consolidated financial results for the quarter ended 30th June, 2020 of Rs.279.90 is on account of gain from
- transfer of intimate hygiene brand Vwash and reimbursement of onetime costs. The figures for the quarter ended 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the unaudited
- published year to date figures upto the third quarter ended 31st December, 2019.
- 8 The list of subsidiaries as of 30th June, 2020 is provided in Annexure A.
- 9 The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals. 10 As at 30th June 2020, pursuant to Employee Stock Options Scheme 2016, 445,913 options were outstanding, which upon exercise are convertible into equivalent
- 11 The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees,
- vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the quarter ended 30th June, 2020.
- 12 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 13 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited Annexure A

number of equity shares.

List of entities included in the consolidated financial results for the guarter ended 30 June 2020

 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals Europe Ltd., U.K. 3.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals SK, S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 6.Glenmark Holding S.A. 7.Glenmark Pharmaceuticals S.R.L 8.Glenmark Pharmaceuticals SP z.o.o. 9. Glenmark Pharmaceuticals Inc. 10. Glenmark Therapeutics Inc. 11. Glenmark Farmaceutica Ltda 12. Glenmark Generics S.A 13. Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14.Glenmark Pharmaceuticals Peru SAC 15.Glenmark Pharmaceuticals Colombia SAS, Colombia 16.Glenmark Uruguay S.A. 17.Glenmark Pharmaceuticals Venezuela, C.A 18. Glenmark Dominicana SRL 19. Glenmark Pharmaceuticals Egypt S.A.E. 20. Glenmark Pharmaceuticals FZE 21. Glenmark Impex L.L.C 22. Glenmark Philippines Inc. 23. Glenmark Pharmaceuticals (Nigeria) Ltd. 24. Glenmark Pharmaceuticals Malaysia Sdn Bhd 25. Glenmark Pharmaceuticals (Australia) Pty Ltd 26. Glenmark South Africa (pty) Ltd 27. Glenmark Pharmaceuticals South Africa (pty) Ltd 28. Glenmark Pharmaceuticals (Thailand) Co. Ltd 29. Glenmark Pharmaceuticals B.V. 30. Glenmark Arzneimittel Gmbh 31. Glenmark Pharmaceuticals Canada Inc. 32. Glenmark Pharmaceuticals Kenya Ltd 33. Glenmark Therapeutics AG (liquidated with effect from 2 December 2019) 34. Viso Farmaceutica S.L., Spain 35.Glenmark Specialty SA 36.Glenmark Pharmaceuticals Distribution S.R.O. 37.Glenmark Pharmaceuticals Nordic AB 38.Glenmark Ukraine LLC 39.Glenmark-Pharmaceuticals Ecuador S.A. 40. Glenmark Pharmaceuticals Singapore Pte. Ltd. 41. Ichnos Sciences Biotherapeutics SA (Formerly known as Glenmark Biotherapeutics SA) 42.Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) 43.Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited) 42. Glenmark Distribuidora De Medicamentos E Produtos Cosmeticos Ltda. (w.e.f. 20 March 2020)

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director Mumbai, August 14, 2020

financialexp.epa



For Advertising in

TENDER PAGES

Contact JITENDRA PATIL

> Mobile No.: 9029012015 Landline No.: 67440215



महाराष्ट्र शासन

साहाय्यक आयुक्त, समाजकल्याण, मुंबई उपनगर जिल्हा दूरध्वनी क्र.: २५२२२०२३, ई-मेल: spldswo_mumsub@yahoo.co.in

जाहीर आवाहन

या कार्यालयाकड्न शिष्यवृत्तीची रक्कम कोषागारातून पारित झाल्यानंतर बँकेमार्फत महाविद्यालय व विद्यार्थ्यांच्या खात्यात जमा करण्यात येते तथापि सन २०११-१२ ते सन २०१७-१८ च्या दरम्यान पारित शिष्यवृत्ती देयकामध्ये महाविद्यालय व विद्यार्थ्यांनी बँक खाते क्रमांक योग्य नमद न केल्यामुळे शिष्यवृत्तीची रक्कम लाभार्थ्यांना अदा करता आलेली नाही.

मुंबई उपनगर जिल्ह्यातील महाविद्यालयांनी **तात्काळ** या कार्यालयाशी संपर्क साधून शिष्यवृत्तीची रक्कम प्राप्त करून घ्यावी, अन्यथा शिष्यवृत्तीची रक्कम शासनखाती जमा करण्यात येईल व सदर कारणामुळे मागासवर्गीय विद्यार्थी शिष्यवृत्तीपासुन वंचित राहिल्यास याची सर्वर्स्व जबाबदारी प्राचार्याची राहील, याची नोंद घ्यावी,

(समाधान इंगळे) साहाय्यक आयुक्त समाजकल्याण डीजीआयपीआर २०२०-२१/५२८ मुंबई उपनगर जिल्हा

glenmark

PHARMACEUTICALS LTD. Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Statement of Unaudited Financial Results for the quarter ended 30th June, 2020

Standalone

(Rs. in Millions)

Consolidated

	2000 NO 76	Standalone				Consolidated			
Sr. No.	(Refer notes below)	Quarter ended 30-06-2020 (Unaudited)	Quarter ended 31-03-2020 (Audited)	Quarter ended 30-06-2019 (Unaudited)	Year ended 31-03-2020 (Audited)	Quarter ended 30-06-2020 (Unaudited)	Quarter ended 31-03-2020 (Audited)	Quarter ended 30-06-2019 (Unaudited)	Year ended 31-03-2020 (Audited)
1	Revenue from operations								
	(a) Net sales	16,524.45	15,616.96	14,552.33	64,912.00	23,092.83	27,112.73	22,836.04	103,972.28
	(b) Other operating income	304.77	460.38	435.60	2,214.31	355.04	562.16	392.75	2,437.41
	Total Revenue from operations	16,829.22	16,077.34	14,987.93	67,126.31	23,447.87	27,674.89	23,228.79	106,409.69
m	Other income	1,348.49	2,512.88	685.41	6,067.88	585.14	441.45	16.69	1,596.02
111	807*C3 0 505 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	18,177.71		15,673.34	73,194.19	24,033.01	28,116.34	23,245.48	
(A)1007	Total income (I + II)	10,177.71	18,590.22	15,075.54	73,134.13	24,000.01	20,110.34	23,243.46	108,005.7
IV	Expenses		F 400 40	E 400 70	00 540 04	704400	F 0 40 04	0.000.05	05.444.7
	(a) Cost of materials consumed	5,917.41	5,496.43	5,193.73	22,519.81	7,041.92	5,940.01	6,086.05	25,414.7
	(b) Purchase of stock-in-trade	762.73	836.13	966.13	3,652.41	217.83	1,804.32	2,587.00	10,290.8
	(c) Changes in inventories of finished goods,								
	work-in-progress and stock-in-trade	(157.24)	518.87	(92.84)	487.68	823.91	2,016.17	(572.03)	1,280.8
	(d) Employee benefits expense	2,372.36	2,423.94	2,200.16	10,723.27	5,096.06	5,242.40	4,866.90	22,547.7
	(e) Finance costs	599.38	635.73	680.76	2,563.90	937.40	984.74	930.15	3,773.1
	(f) Depreciation and Amortisation expense	358.09	352.27	321.65	1,385.38	1,132.22	1,262.75	907.31	4,171.6
	(g) Other expenses	2,846.52	4,786.86	3,634.31	16,700.84	5,487.47	8,015.12	6,841.75	29,894.7
	Total expenses (IV)	12,699.25	15,050.23	12,903.90	58,033.29	20,736.81	25,265.51	21,647.13	97,373.7
V	Profit/(loss) before exceptional items and tax (III-IV)	5,478.46	3,539.99	2,769.44	15,160.90	3,296.20	2,850.83	1,598.35	10,632.0
VI	Exceptional items (Refer note 6)	(279.90)	(185.54)	2,700.44	(185.54)	(279.90)	(328.76)	1,000.00	(328.76
10303		5000 CL PLACE CLASS		2.760.44			0.000 0.000	1 500 25	
VII	Profit/(loss) before tax (V-VI)	5,758.36	3,725.53	2,769.44	15,346.44	3,576.10	3,179.59	1,598.35	10,960.7
VIII	Tax expense :								
	Current tax	1,012.33	657.00	604.77	2,692.37	1,322.78	854.05	959.62	3,961.2
50016	Deferred tax	121.28	(423.34)	(113.76)	(891.41)	(287.10)	122.46	(454.08)	(760.21
IX	Profit/(loss) for the period from		ADD 177 (ADD 157 (ADD	1007 C 2010 C 104 107 200 C	W. 1. 1 100 100 100 100 100 100 100 100 1		0.5000000000000000000000000000000000000		
	continuing operations (VII - VIII)	4,624.75	3,491.88	2,278.43	13,545.48	2,540.42	2,203.08	1,092.81	7,759.7
X	Profit/(loss) for the period from								
	discontinuing operations (VII - VIII)	2	-	2	-	2	1020	27	
XI	Tax expense of discontinuing operations :								
156400	Current tax	- 2		2	-	2	548	100	
	Deferred tax	- 2	340	2	-	2	(*)	¥3	
XII	Profit/(loss) for the period								
510	from discontinuing operations (X - XI)		-	*	_	*	*		
KIII	Profit/(loss) for the period for continuing and								
Sin	discontinuing operations (IX + XII)	4,624.75	3,491.88	2,278.43	13,545.48	2,540.42	2,203.08	1,092.81	7,759.70
αV	Other comprehensive income	7,027,70	0,101.00	2,270.10	10,010.10	2,010.12	2,200.00	1,002.01	7,700.7
VI V	15 15 15 15 15 15 15	5.51	(46.00)	18.03	(00.00)	0.37	276.13	(20 0E)	E0 E
	A (i) Items that will not be reclassified to profit or loss	5.51	(46.08)	10.03	(88.83)	0.37	270.13	(38.25)	52.5
	(ii)Income tax relating to items that will not be	(4.00)	10.40	/E E7\	24.64	(0.00)	(05.04)	1.00	15.0
	reclassified to profit or loss	(1.93)	16.42	(5.57)	34.61	(0.38)	(25.84)	1.22	15.0
	B (i) Items that will be reclassified to profit or loss		-	_	-	259.62	(2,066.47)	412.10	(2,248.33
	(ii)Income tax relating to items that will be					(10.00)	4400 - 41	24.00	1000 100
5555	reclassified to profit or loss				550,000,000	(16.32)	(180.54)	24.99	(276.42
ΧV	Total comprehensive income	4,628.33	3,462.22	2,290.89	13,491.26	2,783.71	206.36	1,492.87	5,302.5
(VI	Total comprehensive income attributable to:						100011-0101	09500040	
	- Non-controlling interests			*		1.33	(1.67)	0.28	0.0
	- Owners of the Company	4,628.33	3,462.22	2,290.89	13,491.26	2,782.38	208.03	1,492.59	5,302.5
IIV	Other equity			102	131,980.47			58 E	60,422.8
VIII	Earning Per Share (EPS) (for continuing operations)				. 20				18
	(of Re. 1/- each) (not annualised)*								
	Basic EPS (in Rupees)	16.39	12.38	8.07	48.00	9.00	7.81	3.87	27.5
	Diluted EPS (in Rupees)	16.39	12.38	8.07	48.00	9.00	7.81	3.87	27.5
ίX	Earning Per Share (EPS) (for discontinuing operations)	10.00	12.00	0.07	10.00	0.00	1.01	0.07	27.0
NIA.	[[리고 B.								
	(of Re. 1/- each) (not annualised)*	100	1290	19.5		425	636	545	
	Basic EPS (in Rupees)			-	[]	_			
VV	Diluted EPS (in Rupees)		(19)		1			*:	
XX	Earning Per Share (EPS) (for continuing and								
	discontinuing operations)								
	(of Re. 1/- each) (not annualised)*	57.501.121	100000000	10421101111	1 3/2/12/12	21/12/2012/2012	0277277	10000 2000) 17 <u>0</u> 000 1000
	Basic EPS (in Rupees)	16.39	12.38	8.07	48.00	9.00	7.81	3.87	27.50
	Diluted EDS (in Bunges)	16 30	12 28	8.07	48.00	9.00	7.91	2.97	27.50

Diluted EPS (in Rupees) * except for the year ended 31 March 2020

The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.

12.38

8.07

48.00

9.00

7.81

3.87

27.50

- 2 The above results were reviewed by the Audit Committee at its meeting held on 13th August, 2020 and approved by the Board of Directors at their meetings held on
- The results for the quarter ended 30th June, 2020 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- Pursuant to the Taxation Law (Amendment) Ordinance 2019 ('Ordinance') Issued by Ministry of Law and Justice (Legislative Department) on 20th September 2019 which is effective 1st April 2019, domestic companies have the option to pay corporate Income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Company upon the amendment made an assessment of the Impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit and other exemptions. The Company has also re-measured its deferred tax liability following the clarification issued by Technical Implementation Group of Ind AS implementation Committee by applying the lower tax rate in measurement of deferred taxes only to extent that the deferred tax liabilities are expected to be reversed in the period during which it expects to be subject to lower tax rate.
- The Company completed its sale of intimate hygiene brand, VWash to Hindustan Unilever Limited during the guarter ended 30th June, 2020.

16.39

- 6 Exceptional item: Exceptional items in the standalone and consolidated financial results for the guarter ended 30th June, 2020 of Rs.279.90 is on account of gain from
- transfer of intimate hygiene brand Vwash and reimbursement of onetime costs. 7 The figures for the quarter ended 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the unaudited
- published year to date figures upto the third quarter ended 31st December, 2019. The list of subsidiaries as of 30th June, 2020 is provided in Annexure A.
- 9 The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- 10 As at 30th June 2020, pursuant to Employee Stock Options Scheme 2016, 445,913 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
- 11 The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Group's financial results for the guarter ended 30th June, 2020.
- 12 Diluted EPS has been computed considering the effect of conversion of ESOPs.
- 13 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Glenmark Pharmaceuticals Limited

epalsembablesegusa 1402020

Annexure A List of entities included in the consolidated financial results for the quarter ended 30 June 2020

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals Europe Ltd., U.K. 3.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals SK, S.R.O. 5.Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 6.Glenmark Holding S.A. 7.Glenmark Pharmaceuticals S.R.L 8.Glenmark Pharmaceuticals SP z.o.o. 9.Glenmark Pharmaceuticals Inc. 10.Glenmark Therapeutics Inc. 11.Glenmark Farmaceutica Ltda 12.Glenmark Generics S.A 13.Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14.Glenmark Pharmaceuticals Peru SAC 15.Glenmark Pharmaceuticals Colombia SAS, Colombia 16.Glenmark Uruguay S.A. 17.Glenmark Pharmaceuticals Venezuela, C.A 18.Glenmark Dominicana SRL 19.Glenmark Pharmaceuticals Egypt S.A.E. 20.Glenmark Pharmaceuticals FZE 21.Glenmark Impex L.L.C 22.Glenmark Philippines Inc. 23.Glenmark Pharmaceuticals (Nigeria) Ltd. 24.Glenmark Pharmaceuticals Malaysia Sdn Bhd 25.Glenmark Pharmaceuticals (Australia) Pty Ltd 26.Glenmark South Africa (pty) Ltd 27. Glenmark Pharmaceuticals South Africa (pty) Ltd 28. Glenmark Pharmaceuticals (Thailand) Co. Ltd 29. Glenmark Pharmaceuticals B.V. 30. Glenmark Arzneimittel Gmbh 31. Glenmark Pharmaceuticals Canada Inc. 32. Glenmark Pharmaceuticals Kenya Ltd 33. Glenmark Therapeutics AG (liquidated with effect from 2 December 2019) 34. Viso Farmaceutica S.L., Spain 35. Glenmark Specialty SA 36. Glenmark Pharmaceuticals Distribution S.R.O. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Ukraine LLC 39. Glenmark Pharmaceuticals Ecuador S.A. 40. Glenmark Pharmaceuticals Singapore Pte. Ltd. 41. Ichnos Sciences Biotherapeutics SA (Formerly known as Glenmark Biotherapeutics SA) 42.Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) 43.Glenmark Life Sciences Limited (Formerly known as Zorg Laboratories Private Limited) 42. Glenmark Distribuidora De Medicamentos E Produtos Cosmeticos Ltda. (w.e.f. 20 March 2020) For and on behalf of the Board of Directors

I Resham Devi Surana, holding 3800 shares

NOTICE

of Reliance Industries Limited, Registered office:3rd Floor, Maker Chambers IV,222, Nariman point, Mumbai - 400021, Folio No.075515197 bearing Share Certificate No.16820598, 16820599, 16820600, 16820601, 16820602 and 16820603 with distinctive nos. from 470218555 to 470218579, 470218580 to 470218604. 470218605 to 470218629, 470218630 to 470218654, 470218655 to 470218679 and 470218680 to 470218704, consisting 25 shares each respectively, total 125 shares are lost and I have applied to the company for issue of duplicate share certificates The public is hereby warned against purchasing or dealing in anyway with the share certificates. The company may issue duplicate share certificates if no objection is received within 15 days of the publication of the advertisement, after which no claim shall be entertained by the company in that behalf.

Resham Devi Surana Place: Mumbai Date:15th Aug,2020 Folio: 075515197

NOTICE REGARDING LOST CERTIFICATE(S) OF

AMARA RAJA BATTERIES LIMITED Registered Address: Renigunta Cuddapah Road, Karakambadi Tirupati, A. P. (india), AP 517520 IN I Saurabh Agrawal residing at 2601, The Imperial, B.B Nakashe Marg, Tardeo, Mumbai Maharashtra, 400034, am the registered holder(s) of the under mentioned shares held in the above said company, hereby give notice that the share certificate(s) in respect of the said shares have been lost and I have applied to the Company for issue of duplicate Further, the said shares have been transferred to IEPF Authority, as the dividend amount remained unpaid. Any person having any objection/claim in respect of the said shares should lodge such claims with the Company at its above referred address within 15 days from this date, else the Company will endorse to the IEPF Authority for releasing the said shares from their

> Folio Share Distinctive Distinctive No. of Equity No. Certificate Nos. No. From No. To Shares 40251 43710 7036501 7036600 100 40251 43714 7036901 7037000 100 40251 1491 14738406 14739405 1000 40251 3283 500 69863049 69863548 40251 3578281 3581280 3000

demat a/c to my/our demat account, without insisting for production of the original share

Date: August 14, 2020 Place: Mumbai

Saurabh Agrawal



Course Duration ((ONLINE)) Date: 20 & 21 Aug. 2020 Timing: 1.00 PM To 6.00 PM

IDEMI, Swatantryaveer Tatya Tope Marg, Chunabhatti, Sion P.O. Mumbai 400022 E-mail ID: training @idemi.org Web: www.idemi.org

After Successful Completion certificate will be issued by Govt. of India.

Fees: 4000+18%GST in the name of IDEMI, Mumbai. For. Whom: Engineers, Architect, Budding Entrepreneurs, Students & Other Interested Candidates

Contact for details in between 10 AM To 6 AM



महाराष्ट्र शासन

सामाजिक न्याय व विशेष साहाय्य विभाग

समाज कल्याण आयुक्तालय, ३, चर्च रोड, पुणे-४११००१. दूरध्वनी क्रमांक २६१२७५६९-०२० / ०२०-२६१३७१८६ ई-मेल- fs.directorsw@gmail.com

अनुसूचित जातीच्या मुलामुलींना परदेशात विशेष अध्ययन करण्यासाठी राजर्षी शाहू महाराज शिष्यवृत्ती योजना - सन २०२०-२१.

''पदव्युत्तर पदवीसाठी पात्रतेत सुधारणा व अर्ज सादर करण्याचा अंतिम दिनांक २८.०८.२०२० च्या मुदतवाढीबाबत''

परदेशात उच्च शिक्षणासाठी प्रवेश मिळालेल्या महाराष्ट्रातील अनुसूचित जाती, नवबौद्ध प्रवर्गातील विद्यार्थ्यांना परदेशामध्ये विशेष अध्ययन करण्यासाठी परदेश शिष्यवृत्तीच्या निवडीसाठी दि. १३.०७.२०२० च्या जाहिरातीद्वारे तसेच दि. २७.०७.२०२०च्या सुधारणेद्वारे अर्ज मागविण्यात येत असल्याबाबतची जाहिरात प्रसिद्ध करण्यात आलेली आहे.

- १. त्यामध्ये सदरील वेबसाइटवरून अर्ज डाऊनलोड करून तो परिपूर्ण भरून व आवश्यक त्या कागदपत्रांसह दिनांक:- १४.०८.२०२० पर्यंत सायंकाळी ५.४५ वाजेपर्यंत हार्ड कॉपी किंवा स्कॅन कॉपी विभागाच्या अर्ज स्वीकृतीसाठीच्या स्वतंत्र swfs.applications@gmail.com या ई-मेलवर सादर करावा. जे विद्यार्थी ई-मेलद्वारे अर्ज पाठवतील त्यांनी ई-मेलद्वारे पाठविलेल्या अर्जाची हार्ड कॉपी पोस्टाने किंवा समक्ष समाज कल्याण आयुक्तालय, ३ चर्च रोड, पुणे- ४११००१ येथे सादर करावी.
- त्याऐवजी खालीलप्रमाणे सुधारणा करण्यात येत आहे.
 - १. शासनाचे दि. ०६.०८.२०२० रोजीचे पत्र व सहपत्र अन्वये, PG साठी Eligibility पुढीलप्रमाणे

२. तसेच PG साठी Eligibility Graduation in Concern Subject असे नमूद आहे.

- ''एखाद्या शाखेतील विद्यार्थ्यास परदेशातील विद्यापीठाने, शासनाने अनुज्ञेय केलेल्या अन्य शाखेअंतर्गत पदव्युत्तर पदवी अभ्यासक्रमासाठी प्रवेश दिला असल्यास सदर प्रवेश परदेश शिष्यवृत्ती योजनेच्या लाभासाठी ग्राह्य धरण्यात यावा. त्यासाठी त्याच शाखेतील अभ्यासक्रमामधील पदवी आवश्यक असणार
- २. तसेच अर्ज सादर करण्याचा अंतिम दिनांक १४.०८.२०२० ऐवजी दि. २८.०८.२०२० असा असेल. सही/-

डीजीआयपीआर २०२०-२१/५२९

ज्न्या इमारतीचे

आयुक्त, समाज कल्याण, महाराष्ट्र राज्य, पुणे

मुंबई इमारत द्रुरुती व पुनर्रचना मंडळ

नवीन इमारतीचे

महाराष्ट्र गृहनिर्माण व क्षेत्र विकास प्राधिकरणाचा घटक



जाहीर सूचना

मुंबई इमारत दुरुस्ती व पुनर्रचना मंडळाच्या अखत्यारीतील पुढील यादीतील पुनर्रचित इमारतींमधील नमूद केलेल्या गाळ्यांचा ज्या संबंधित मूळ भाडेकरु/रहिवाशी यांनी अद्यापपर्यंत ताबा घेतलेला नाही, अथवा सदर गाळ्यांच्या वितरणांसाठी जे मूळ भाडेकरु/ रहिवाशी अद्याप पुढे आलेले नाहीत. अशा पुढील यादीतील सर्व गाळ्यांच्या हक्कासाठी संबंधित मूळ भाडेकरु/रहिवाशी यांनी सदर सूचनेच्या दिनांकापासून १० दिवसांचे आत या कार्यालयास संपर्क साधून गाळ्यांचा ताबा घ्यावा, अन्यंथा सदरह गाळ्यांसदर्भातील मूळ भाडेकरु/रहिवाशी यांना वितरीत केलेली देकारपत्रे अथवा त्यांचे सदर गाळ्यांवरील हक्क कायमस्वरुपी रद्द करण्यात येतील. याची कपया नोंद घ्यावी

गाळा गाळ्याचा

नाव व पत्ता	नाव व पत्ता		क्र.	प्रकार	30
१७-२७	श्री अमेय	१	१०५	निवासी	सदर इमारतीतील गाळा क्रमांकाच्या रकान्यात
दुसरा कोळीवाडा	5500 (64 (A02) - 6	2	508	निवासी	नमूद एकूण १२ गाळ्यांच्या वितरणाशी
199000 00000000		3	२०५	निवासी	संबंधित सर्व मूळ भाडेकरु/रहिवाशी यांना
		8	304	निवासी	कळविण्यात येते की, त्यांनी त्वरीत या
		4	805	निवासी	कार्यालयाशी संपर्क साधून गाळ्यांचा ताबा
	i i	Ę	804	निवासी	घेण्यात यावा.
	1	19	403	निवासी	
		6	408	निवासी	
		9	६०२	निवासी	
		٤0	909	निवासी	
		88	609	निवासी	
		१२	908	निवासी	
४-८-८अ १० मुझावर पाखाडी/दुसरा कोळीवाडा	औदंबर छाया	8	508	निवासी	श्री जी. अलमेडा
बदक चाळ	श्रीकृपा	8	00१	निवासी	श्री जोशी जमनादास केशवजी करिता श्री दिलीप जमनादास जोशी
८ रतनजी पालनजी चाळ	दुर्वांकुर	8	बी-२०४	निवासी	श्री शांताराम चंगू पाटील
NAME OF THE PARTY	3.0		सी-३०८	निवासी	श्री शशीकांत शाम सुर्वे
१३४-१५० थॉवर मॅन्शन	श्री हनुमान निवास	2	404	निवासी	श्री श्यामजी विठ्ठल कुंढडीया
	3	2	£09	निवासी	श्री श्रीहरी लक्ष्मण चित्तयाल
		3	৩१০	निवासी	श्री राजमणी जनार्दन गुंडुका
१३-१३ए नारळवाडी	१३-१३ए	8	308	निवासी	श्री जयराम मुकुंद रहाटे,
100000000000000000000000000000000000000	नारळवाडी	3	303	निवासी	श्रीम. सुनंदा पाठारे,
		3	304	निवासी	श्री जोकिम फुटाडो करिता श्रीम. जेरी जोकिम फुटाडो व इतर वारसदार,
		×	805	निवासी	श्री कमलाकार लक्ष्मीकांत ठाकूर, आर.टी. टेनंट
		4	404	निवासी	श्री शांताराम कृष्णा कोचरेकर,
		Ę	803	निवासी	श्री जगन्नाथ लक्ष्मण तळेकर,
	Î	19	६0५	निवासी	श्री कमलाकार नाथ ठाकूर,
		6	६०६	निवासी	श्री लक्ष्मीकांत विश्वनाथ ठाकूर

(विशाल देशमुख) उपमुख्य अधिकारी / पृगा

मुंबई इमारत दुरुस्ती व पुनर्रचना मंडळ, मुंबई

CPRO/A/132

Glenn Saldanha

Chairman & Managing Director